Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Asian Pacific Journal of Tropical Medicine ; 15(9):400-409, 2022.
Article in English | EMBASE | ID: covidwho-2080621

ABSTRACT

Objective: To evaluate long-term effects of COVID-19, and to determine the risk factors in long-COVID in a cohort of the Turkish Thoracic Society (TTS)-TURCOVID multicenter registry. Method(s): Thirteen centers participated with 831 patients;504 patients were enrolled after exclusions. The study was designed in three-steps: (1) Phone questionnaire;(2) retrospective evaluation of the medical records;(3) face-to-face visit. Result(s): In the first step, 93.5% of the patients were hospitalized;61.7% had a history of pneumonia at the time of diagnosis. A total of 27.1% reported clinical symptoms at the end of the first year. Dyspnea (17.00%), fatigue (6.30%), and weakness (5.00%) were the most prevalent long-term symptoms. The incidence of long-term symptoms was increased by 2.91 fold (95% CI 1.04-8.13, P=0.041) in the presence of chronic obstructive pulmonary disease and by 1.84 fold (95% CI 1.10-3.10, P=0.021) in the presence of pneumonia at initial diagnosis, 3.92 fold (95% Cl 2.29-6.72, P=0.001) of dyspnea and 1.69 fold (95% Cl 1.02-2.80, P=0.040) fatigue persists in the early-post-treatment period and 2.88 fold (95% Cl 1.52-5.46, P=0.001) in the presence of emergency service admission in the post COVID period. In step 2, retrospective analysis of 231 patients revealed that 1.4% of the chest X-rays had not significantly improved at the end of the first year, while computed tomography (CT) scan detected fibrosis in 3.4%. In step 3, 138 (27.4%) patients admitted to face-to-face visit at the end of first year;at least one symptom persisted in 49.27% patients. The most common symptoms were dyspnea (27.60%), psychiatric symptoms (18.10%), and fatigue (17.40%). Thorax CT revealed fibrosis in 2.4% patients. Conclusion(s): COVID-19 symptoms can last for extended lengths of time, and severity of the disease as well as the presence of comorbidities might contribute to increased risk. Long-term clinical issues should be regularly evaluated after COVID-19. Copyright © 2022 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer Medknow.

3.
Gazi Medical Journal ; 32(2):213-218, 2021.
Article in English | Web of Science | ID: covidwho-1257156

ABSTRACT

Objective: The aim of the study is to compare the differences between COVID-19 pneumonia and other viral pneumonia (OVP) in terms of demographic, clinical and radiological features. Methods: This retrospective cohort study was conducted in Gazi University Hospital between 11 March and 24 May 2020. Patients, admitted to the hospital with suspected COVID-19 infection aged >18 years and those who had pneumonia on chest computed tomography (CT) scan were evaluated. SARS-CoV-2 RT-PCR and multiplex PCR, for other respiratory viruses, were performed. Patients with a positive SARS-CoV-2 PCR were included in "COVID-19 pneumonia" group and those who had a positive result for any other respiratory viruses and two consecutive negative results for SARS-CoV-2 were included in the "OVP" group. Two groups were compared in terms of clinical, laboratory and chest CT findings. Results: Of the 63 patients included in the study, 45 had COVID-19 pneumonia and 18 had OVP. Cough, nasal congestion, sputum production and leukocytosis were more common in the OVP group while leukopenia was more common in the COVID-19 pneumonia (p<0.05). The distribution pattern of parenchymal lesions on chest CT was more likely to be predominantly peripheral and posterior in COVID-19 pneumonia compared to OVP. Bilateral involvement was also more frequent in COVID-19 group compared to OVP (p<0.05). Conclusion: Distinguishing COVID-19 pneumonia from OVP with clinical and laboratory findings is difficult. Chest CT findings such as peripheral and posterior distribution of the parenchymal lesions and bilateral involvement may help to differentiate COVID-19 pneumonia from OVP.

SELECTION OF CITATIONS
SEARCH DETAIL